Gus Alva, MD; and Hara Oyedeji, MSN, MSEd, PMHNP-BC, APRN discuss how schizophrenia encompasses 3 distinct symptom domains beyond merely hallucinations, the limitations of current dopamine-blocking treatments, and the promising emergence of xanomeline trospium chloride as a novel muscarinic agonist that offers hope for more comprehensive treatment of this complex neuropsychiatric condition affecting millions worldwide.
Panelists discuss how schizophrenia affects 3.5 million Americans through 3 distinct symptom domains––positive symptoms (hallucinations), negative symptoms (social isolation, reduced functioning), and cognitive symptoms ––rather than just the commonly perceived “hearing voices.”
Panelists discuss how current standard treatments primarily address positive symptoms through D2 receptor blockade medications and cognitive behavioral therapy but often provide only partial efficacy while potentially worsening negative and cognitive symptoms that most impact daily functioning.
Panelists discuss how the biggest unmet needs in schizophrenia treatment include limited mechanistic options beyond D2 blockade, significant side effect burdens (weight gain, metabolic issues, cognitive blunting), and the challenge of balancing treatment benefits against risks that can lead to medication non-adherence.
Panelists discuss how early intervention is crucial because psychosis causes brain atrophy over time. Clinicians should ask broader questions such as “What would you change about your life?” to identify negative and cognitive symptoms that patients prioritize, while maintaining an aspirational and empowering approach to treatment goals.
Panelists discuss how to set realistic expectations with patients with schizophrenia by being up-front and honest while establishing open communication and strong rapport from the beginning of treatment.
Panelists discuss how the new medication xanomeline/trospium chloride represents a paradigm shift in schizophrenia treatment through its novel muscarinic agonist mechanism that targets presynaptic dopamine activity rather than traditional postsynaptic D2 blockade.
Panelists discuss how xanomeline/trospium chloride has shown effectiveness in clinical practice across multiple symptom domains, with patients demonstrating improved engagement, socialization, and daily functioning alongside a different but manageable adverse effect profile.
Panelists discuss how to appropriately select patients for xanomeline/trospium chloride treatment, emphasizing the importance of early intervention, comprehensive medication reconciliation, and proper patient education about dosing requirements and potential adverse effects.
Panelists discuss how emerging treatment modalities including digital therapeutics and novel pharmaceutical agents represent an exciting new frontier that could elevate the standard of care for patients with schizophrenia when combined with traditional approaches.
